ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده: 2

Clinical trials from which the Breast Cancer Index data are drawn

Clinical trials from which the Breast Cancer Index data are drawn
Citation Trial name Intervention
Zhang Y, et al[1] Stockholm Tam Tamoxifen for 2 versus 5 years versus nothing (tamoxifen 2 and 5 years combined in analysis)
Sgroi DC, et al[2] MA17 Tamoxifen for 5 years, then letrozole versus placebo (extended; case control)
Sgroi DC, et al[3] ATAC Tamoxifen versus anastrozole versus combined (combined not included in analysis)
Sestak I, et al[4] ATAC
Bartlett JM, et al[5] aTTom Tamoxifen at least 4 years, then tamoxifen versus nothing (extended; only the node positive)
Bartlett JM, et al[6] aTTom
Sgroi DC, et al[7] aTTom
Noordhoek I, et al[8] IDEAL Tamoxifen or tamoxifen-aromatase inhibitor or aromatase inhibitor for 5 years, then 2.5 versus 5 years of letrozole (extended)
Mamounas EP, et al[9] B-42 Endocrine therapy for 5 years, then letrozole versus placebo (extended)
References:
  1. Zhang Y, Schnabel CA, Schroeder BE, et al. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res 2013; 19:4196.
  2. Sgroi DC, Carney E, Zarrella E, et al. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst 2013; 105:1036.
  3. Sgroi DC, Sestak I, Cuzick J, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 2013; 14:1067.
  4. Sestak I, Buus R, Cuzick J, et al. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 2018; 4:545.
  5. Bartlett JM, Sgroi DC, Treuner K, et al. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial. Ann Oncol 2019; 30:1776.
  6. Bartlett JM, Sgroi DC, Treuner K, et al. Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study. Clin Cancer Res 2022; 28:1871.
  7. Sgroi DC, Treuner K, Zhang Y, et al. Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study. Breast Ca Res 2022; 24:90.
  8. Noordhoek I, Treuner K, Putter H, et al. Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy. Clin Cancer Res 2021; 27:311.
  9. Mamounas EP, Bandos H, Rastogi P, et al. Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42. J Clin Oncol 2021; 39:S501.
Graphic 143117 Version 1.0